Quality of life in uncomplicated diverticular disease: Is it another good reason for the treatment?

Comparato, G.; Fanigliulo, L.; Cavallaro, L.G.; Aragona, Giovanni; Cavestro, Giulia Martina; Liatopoulou, S.; Carloni, C.; Nervi, G.; Muzzetto, P.; Iori, Veronica; Maino, M.; Franzè, A.; Mario, F. Di

doi:10.1016/s1590-8658(06)80480-9

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, mesalazine was found more effective than rifaximin both in the treatment of symptomatic diverticular disease [6] with regard to prevention of recurrent attacks of acute diverticulitis [3]. Mesalazine was also found more effective than rifaximin in improving quality of life in those with uncomplicated diverticulosis [12].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Continuous Versus Cyclic Mesalazine Therapy for Patients Affected by Recurrent Symptomatic Uncomplicated Diverticular Disease of the Colon

et al. 2007

View full text Add to dashboard Cite

Forty consecutive patients affected by recurrent attacks of symptomatic uncomplicated diverticular disease of the colon were evaluated to investigate the effectiveness of 2 different mesalazine therapeutic schedules in preventing recurrence of the disease. The patients were randomly enrolled and treated with mesalazine 1.6 g/d (group A) or mesalazine 1.6 g/d 10 days per month (group B). Thirty-four patients completed the study (85%): 3 (7.5%, 1 in group A and 2 in group B) were lost to follow-up, 2 (5%, both group B) were withdrawn from the study for protocol violation, and 1 (2.5%) for hospital admission for stroke (group A). Twenty-three patients (67.65%) were symptom free after 24 months of treatment (overall symptomatic score, 0): 14 of 18 in group A (per-protocol, 77.78%; intention to treat, 70% [95% confidence interval [CI], 61.5-91.8]), 9 of 16 in group B (per protocol, 56.25%; intention to treat, 45% [95% CI, 61.5-91.8]; P< 0.05). Four patients (10%) improved, but were not completely symptom free. Six patients (15%) showed recurrence of symptoms: 1 in group A (5.56%) and 5 in group B (31.25%; P < 0.005; overall symptomatic score, 68). Daily mesalazine supplying seems to be more effective than cyclic supplying in maintaining remission in recurrent symptomatic uncomplicated diverticular disease.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Patients symptom free throughout the follow-up period (n; see text for details) Recurrence of symptoms throughout the follow-up period experienced irregularly slight or mild symptoms throughout follow-up: 2 in group A (40%) and 3 in group B (60%; P = NS; overall symptomatic score,12)…”

mentioning

confidence: 99%